A clinical study on safety and efficacy of sorafenib as maintenance chemotherapy after percutaneous isolated hepatic perfusion chemotherapy (PIHP) for advanced hepatocellular carcinoma
Phase 1
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000008689
- Lead Sponsor
- Department of hepato-biliary-pancreatic surgery, Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a history of molecular- target therapy including sorafenib. 2)Patients with a history of hypersensitivity of sorafenib 3)Patients who are pregnant or on nurse. 4)Patients who are on dialysis 5)Patients with uncontrolled hypertension 6)Patients with a history of thrombosis, embolism, or ischemic Heart Disease 7)Patients with brain metastasis 8)Patients with esophageal varix with bleeding tendency 9)Patients with gastrointestinal bleeding within one month 10)Patients with ongoing or history of hepatic encephalopathy 11)Patients who undergo rifampin 12)Patients with HIV or AIDS 13)Patients with synclonous double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method One year overall survival
- Secondary Outcome Measures
Name Time Method Progression or recurrence free survival Overall survival Safety of sorafenib administration after PIHP